Long-term Study Results Show That PFO Closure is More Effective Than Medical Management in Preventing Recurrent Stroke
Final results from the RESPECT study reported at TCT 2016
Final results from the RESPECT trial found that percutaneously closing a patent foramen ovale (PFO) using the Amplatzer PFO Occulder was superior to medical management in the prevention of recurrent ischemic stroke in patients who previously had a cryptogenic stroke. The U.S. Food and Drug Administration (FDA) recently approved the device for recurrent stroke prevention in patients with a PFO and history of cryptogenic stroke on the basis of these data. A PFO is a small hole between the atria that did not close completely early in life and which can allow a venous system clot to enter the left atrium and travel to the brain causing a stroke. Current guidelines call for a medical management with anticoagulants or antiplatelet drugs for patients with PFO following a cryptogenic stroke.
Click here to read more.
2017 AANS/CNS Section on Pediatric Neurological Surgery
Nov. 28-Dec. 1, 2017; Houston
2nd Homburg ICP and Hydrocephalus Workshop
Nov. 28-30, 2017; Germany
22nd Instructional Course and 45th Annual Meeting of the Cervical Spine Research Society
Nov. 29, 2017 - Dec. 2, 2017; Hollywood, Fla.